Optibrein SRL
Optibrein reported revenue of 22,100 € for the 2025 financial year (annual accounts filed with the NBB on 20 Jun 2026).
The score of Optibrein shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +1413 % Total assets +138 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Optibrein's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 22,100 € | ||||
| Net result | 614 € | ||||
| Equity | −20,611 € | ||||
| Cash | 1,793 € | ||||
| EBITDA | 6,261 € | ||||
| Total assets | 15,965 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Jun 2026
- Year ended 31 Dec 2024filed on 14 Jun 2025
- Year ended 31 Dec 2023filed on 19 May 2024
- Year ended 31 Dec 2022filed on 11 Jun 2023
- Year ended 31 Dec 2021filed on 14 Apr 2022
Optibrein's financial analysis
- Solvency-129.1%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Optibrein
Optibrein's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0689.969.215
- VAT number
- BE0689969215
- Peppol
- Registered · 0208:0689969215 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Feb 2018
- Registered office
- 3271 Scherpenheuvel-Zichem
- Latest accounts
- 2025 · filed on 20 Jun 2026
- Activity
- Activities in the field of nutrition (NACE 86995)
Optibrein (SRL) has been based in Scherpenheuvel-Zichem since 2018, active in: activities in the field of nutrition. For 2025, it reports revenue of 22,100 €, a net profit of 614 € and equity of −20,611 €. Its solvency stands at -129.1%, below the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Optibrein
Companies in the same business, of comparable size and area, outside its group.
- GEA Training en Consulting Other education n.e.c. Zwalm · balance sheet 27,763 €
- Vantricht Solutions Other education n.e.c. Willebroek · balance sheet 63,057 €
- AZ Projects All other professional, scientific and technical activities n.e.c. Lummen · balance sheet 62,035 €
- Haptis Other human health activities n.e.c. Ramillies · balance sheet 388,268 €
- Podologisch Centrum Focus (P.C.F.) Other human health activities n.e.c. Kortenberg · balance sheet 27,072 €
- MCH Operations Other human health activities n.e.c. Heusden-Zolder · balance sheet 5,677 €
- Ospoplus Physiotherapy activities Kortenberg · balance sheet 1,147 €
- Hoorcentrum Van den Bosch Other human health activities n.e.c. Duffel · balance sheet 48,097 €
Frequently asked questions about Optibrein
What is the revenue of Optibrein?
According to the 2025 annual accounts filed with the NBB, the revenue of Optibrein amounts to 22,100 €.
What is the VAT number of Optibrein?
In Belgium, the VAT number is the company number prefixed with BE: BE0689969215 for Optibrein, if the company is VAT-registered. Its company number (CBE) is 0689.969.215.
Where is the registered office of Optibrein?
According to the CBE register, the registered office of Optibrein is in 3271 Scherpenheuvel-Zichem.
What is the equity of Optibrein?
At the close of the 2025 financial year, the equity of Optibrein amounts to -20,611 €, a solvency of -129.1% of total assets.
Who manages Optibrein?
The register lists 2 active mandates at Optibrein. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Optibrein
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →